Panbela Therapeutics EBIT

The latest EBIT for PBLA is $-44M as of September 2024. That compares with $-32M in the prior-year period — down 40.4% year over year. That is below the Technology sector average of $80T. Investors often review this figure alongside Panbela Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PBLA's EBIT moved from $-32M to $-44M — a 40.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Panbela Therapeutics's operating scale or balance-sheet position.

Against Technology companies, PBLA currently prints $-44M for EBIT, while the sector average sits near $80T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Panbela Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-44M for PBLA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $80T. Explore the charts below for those layers of context.

After noting PBLA's EBIT ($-44M), review year-over-year change from $-32M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.